WO1993002558A1 - Method and formulation for reducing microbial populations - Google Patents

Method and formulation for reducing microbial populations Download PDF

Info

Publication number
WO1993002558A1
WO1993002558A1 PCT/US1991/003796 US9103796W WO9302558A1 WO 1993002558 A1 WO1993002558 A1 WO 1993002558A1 US 9103796 W US9103796 W US 9103796W WO 9302558 A1 WO9302558 A1 WO 9302558A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
lactobacillus
whey
sugar
oral administration
Prior art date
Application number
PCT/US1991/003796
Other languages
French (fr)
Inventor
Ivan A. Casas-Perez
Original Assignee
Biogaia Biologics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Biologics Ab filed Critical Biogaia Biologics Ab
Priority to PCT/US1991/003796 priority Critical patent/WO1993002558A1/en
Publication of WO1993002558A1 publication Critical patent/WO1993002558A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/20Animal feeding-stuffs from material of animal origin
    • A23K10/26Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
    • A23K10/28Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin from waste dairy products
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065Microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/179Sakei
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87Re-use of by-products of food processing for fodder production

Definitions

  • This invention relates generally to a method and composition for reducing microbial populations, and more particularly, to a composition containing Lactobacillus and a carbohydrate for use in decreasing the numbers of pathogens in the gastrointestinal tract which do not utilize lactose, such as Salmonella.
  • Lactobacillus reuteri, L. animalis. and L. salivarius are naturally occurring microorganisms in the GI tract of animals including domestic avian species (Sarra, et al., 1985, System Appl. Microbiol 6:86-89). This paper and all other papers cited herein are hereby incorporated herein by reference.
  • Lactobacillus reuteri is a symbiotic resident of the gastrointestinal (GI) tracts of humans, swine and other animals.
  • the neotype strain of L. reuteri is DSM 20016 (ATCC No. 53609).
  • This strain and strain 1063 (ATCC No. 53608), discussed in the co-pending application, are available to the public at the American Type Culture Collection (Rockville, MD) having been deposited therein April 17, 1987.
  • the GI tract of animals is a complex ecosystem harboring an estimated 300-500 species of microorganisms, known collectively as the indigenous microbiota or microflora.
  • enteric diseases Under certain conditions some members of the indigenous microbiota can become opportunistic pathogens causing a variety of enteric diseases. More often, however, pathogens gain access to the GI tract as contaminants in food or water. Notable among the latter . are a number of bacterial genera including Escherichia. Salmonella, Shi ⁇ ella, ⁇ ersina. Vibrio, Campylobacter and Clostridiurrt- as well as viruses (e.g., roto-, astro- and ciliciviruses) and intestinal parasites (e.g., Giardia and Entamoeba species) . Acute and chronic enteric diseases caused by these and other microorganisms occur worldwide causing considerable human misery and loss of economically important animals. Certain microbial activities have also been associated with production of mutagens within the GI trac .
  • the indigenous microbiota can provide their hosts with an assortment of benefits including among others protection against enteric pathogens (a process known as colonization resistance or competitive exclusion) , stimulation of normal development and function of the GI mucosa, production of various vitamins and other nutrients, and re-metabolism of the host's abundant endogenous mucosal tissue.
  • Lactobacillus plantarum strains are grown commercially in large amounts and used as starter cultures for the commercial preservation of a variety of human foods (meats, vegetables, and dairy products) and animal foods (silage). Lactobacillus acidophilus strains are grown commercially in large amounts to be added to human (e.g., milk) or animal (feedstuffs) foods as a means of introducing these bacteria into the GI tract where they can exert beneficial effects. Although these bacteria are likely to be already present in the GI tract their numbers may vary widely from individual to individual, and therefore beneficial effects of these bacteria may not be present in persons deficient in these bacteria.
  • Lactobacillus reuteri was previously found to be recoverable from the stools of piglets after the piglets had been fed large quantities of the cells (co-pending application) . It was hypothesized in the co-pending application that such cells could be used, possibly in conjunction with glycerol, as a growth and health aid for these animals. Evidence has been obtained (and presented below) that L.reuteri may be administered to poultry as a means of competitively excluding salmonellae.
  • the invention is for a formulated product that may be used as an animal feed additive and that includes isolated and identified pure culture(s) of naturally occurring gastrointestinalmicroorganisms, for example, Lactobacillus reuteri, L. animalis, and/or L. salivarius.
  • the formulated product also includes a sugar source.
  • the invention also includes a method of feeding the formulation to animals.
  • the sugar source is whey, when animals which do not metabolize lactose such as chickens are used, because whey contains the sugar lactose and is an easily obtainable and voluminous waste product.
  • the formulation of the invention when fed to animals provides a means to decrease populations of undesirable gastrointestinal microbes and results in increased weight gain of the animals, especially under the less than optimum growth conditions normally present in commercial livestock environments.
  • group animals of a particular species or group of species which share in common a tendency to have a similar gastrointestinal Lactobacillus flora and a similar inability to metabolize a sugar which is metabolizable by the Lactobacillus flora.
  • the formulation discussed in detail herein has been devised for poultry but is adaptable to other animals, and includes a source of lactose which is not metabolizable by poultry.
  • control weights no whey, no L. reuteri at each weight day were made equal to 100%.
  • the invented formulation may be used as a food or food additive mixture for animals grown commericially, such as poultry. It provides a product that results in rapid weight gain for growing animals, and decreases the number of pathogenic microorganisms in the gastrointestinal tract, thereby resulting in increased productivity and decreased animal mortality.

Abstract

A formulation including one or more pure cultures of Lactobacillus, such as L.reuteri, L.animalis and L.salivarius and a sugar source, such as whey and a method of feeding animals which utilizes the formulation to be ingested by the animals with their normal food.

Description

METHOD AND FORMULATION FOR REDUCING MICROBIAL POPULATIONS
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates generally to a method and composition for reducing microbial populations, and more particularly, to a composition containing Lactobacillus and a carbohydrate for use in decreasing the numbers of pathogens in the gastrointestinal tract which do not utilize lactose, such as Salmonella.
Description of the Related Art
Lactobacillus reuteri, L. animalis. and L. salivarius are naturally occurring microorganisms in the GI tract of animals including domestic avian species (Sarra, et al., 1985, System Appl. Microbiol 6:86-89). This paper and all other papers cited herein are hereby incorporated herein by reference.
As disclosed in co-pending application Serial No. 07/268,361 filed September 19, 1988, the disclosure of which is incorporated herein, Lactobacillus reuteri is a symbiotic resident of the gastrointestinal (GI) tracts of humans, swine and other animals. The neotype strain of L. reuteri is DSM 20016 (ATCC No. 53609). This strain and strain 1063 (ATCC No. 53608), discussed in the co-pending application, are available to the public at the American Type Culture Collection (Rockville, MD) having been deposited therein April 17, 1987. The GI tract of animals is a complex ecosystem harboring an estimated 300-500 species of microorganisms, known collectively as the indigenous microbiota or microflora. Despite over 100 years of intensive research in the field of intestinal microbiology much remains to be learned about these microorganisms, the complex interrelationships that exist between the different species, and the nature of the symbiotic relationships existent between the microbiota and their host.
Under certain conditions some members of the indigenous microbiota can become opportunistic pathogens causing a variety of enteric diseases. More often, however, pathogens gain access to the GI tract as contaminants in food or water. Notable among the latter . are a number of bacterial genera including Escherichia. Salmonella, Shiσella, ϊersina. Vibrio, Campylobacter and Clostridiurrt- as well as viruses (e.g., roto-, astro- and ciliciviruses) and intestinal parasites (e.g., Giardia and Entamoeba species) . Acute and chronic enteric diseases caused by these and other microorganisms occur worldwide causing considerable human misery and loss of economically important animals. Certain microbial activities have also been associated with production of mutagens within the GI trac .
It is also known that other members of the indigenous microbiota exist in a symbiotic or synergistic relationship with their host contributing in many positive ways to the host's general health and well-being. It is well-known that germ-free animals are very susceptible to pathogens and have poorly developed GI tracts. In return for the nutrient-rich and stable ecosystem provided for them, the indigenous microbiota can provide their hosts with an assortment of benefits including among others protection against enteric pathogens (a process known as colonization resistance or competitive exclusion) , stimulation of normal development and function of the GI mucosa, production of various vitamins and other nutrients, and re-metabolism of the host's abundant endogenous mucosal tissue. It has been reported on numerous occasions that the enteric lactobacilli (i.e., bacteria belonging to the genus Lactobacillus which reside in the GI tract and which include a large number of nonpathogenic, non-toxic bacteria) play an important role in the health and well- being of their human and animal hosts. Included in this role is their ability to regulate conditions in the GI tract so that the different populations of microorganisms in this system are kept in a healthy balanced state (Fuller, 1977, Br. Poultry Sci. 18:85-94). Certain Lactobacillus species in fact are added to human and animal foodstuffs either to preserve them, enhance their flavors and/or exert other beneficial effects in the GI tract. Lactobacillus plantarum strains, for example, are grown commercially in large amounts and used as starter cultures for the commercial preservation of a variety of human foods (meats, vegetables, and dairy products) and animal foods (silage). Lactobacillus acidophilus strains are grown commercially in large amounts to be added to human (e.g., milk) or animal (feedstuffs) foods as a means of introducing these bacteria into the GI tract where they can exert beneficial effects. Although these bacteria are likely to be already present in the GI tract their numbers may vary widely from individual to individual, and therefore beneficial effects of these bacteria may not be present in persons deficient in these bacteria. Reports on the beneficial effects resulting from the oral administration of live Lactobacillus cultures have increased in recent years with findings that dietary Lactobacillus therapy affords protection from colon cancer for human populations on western diets, reduces the incidence of experimentally induced large bowel tumors in rats, reduces the fecal concentration of bacterial enzymes known to catalyze the conversion of procarcinogens to proximal carcinogens in humans, and reduces the serum cholesterol levels in swine.
Themetabolic endproducts ofLactobacillus metabolism, such as acetic acid, lactic acid and hydrogen peroxide, are well-known for their antimicrobial activities. They are believed to play a significant role in maintaining proper conditions within the GI tract. Some lactobacilli produce bacteriocins or bacteriocin-like proteins which also exhibit bacteriocidal activity toward other members of that species or closely related species. Reports have appeared concerning low molecular weight, antimicrobial substances produced by lactobacilli. With the exception of reuterin which is produced by Lactobacillus reuteri (copending application) none of these low molecular weight substances has been identified and these reports have not been confirmed. In fact, some of these substances have proven to be none other than lactic acid, acetic acid or hydrogen peroxide.
Several studies have been conducted to determine the effect of lactobacilli on the performance of domestic avian species. Some of these studies indicate that dosing broilers with L. acidophilus improved their growth (Tortuero, 1973, Poultry Sci. 52:197-203, and Dilworth and Day, 1978, Poultry Sci. 57:1101). An increase in egg production as a result of addition of lactobacilli to laying hens feed has also been reported (Hargis and Creger, 1978, Poultry Sci. 57:1103). Improvement of young turkeys' body weight and feed efficiency was obtained with a Lactobacillus product added to the feed (Francis et al., 1978, Poultry Sci. 57:1687- 1689). Similar effects were reported (Potter et al., 1986, Poultry Sci. (Suppl. 1) 65:107) when L. acidophilus in combination with varying protein levels was fed to turkeys up to 12 weeks of age, but no difference with the controls was observed at 16 weeks. Dosage of 107 colony forming units (CFU) and higher depressed chick growth (Watkins and Kratzer, 1982, Poultry Sci. 61:1565, and, 1984, Poultry Sci. 63:1671-1673).
Other strains of lactobacilli did not stimulate broilers weight gain (Watkins and Kratzer, 1984), and did not stimulate egg production (Goodling et al., 1987, Poultry Sci. 66:480-485). Damron et al. (1981, Poultry Sci. 60:1350-1351) did not find any beneficial effect of L. acidophilus and other lactobacilli cultures in turkey breeder hens. Nurmi and Rantala (1973, Nature 241:210-211) demonstrated that the intestinal microflora present in some adult chickens (i.e. the cecal microflora) interferes with colonization by salmonellae of newly hatched chicks. The application of this concept, known as the Nurmi concept or competitive exclusion, has been successfully tested in some laboratories and is also used commercially (Watkins and Miller, 1983, Poultry Sci. 62:1772-1779; Wierup et al., 1988, Poultry Sci. 67:1026-1033; Impey et al., 1982, J. Hyg. Camb. 89:749; Snoeyembos et al., 1978, Avian Dis. 22:273-287). There are many problems associated with this method, in particular, a lack of adequate selective isolation and characterization techniques to study and consistently obtain cecal flora preparations (Bailey, 1988, Poultry Sci. 67:928-932; Mead and Impey, 1986, J. Bacteriol. Symp. Suppl. 675-755; Soerjadi et al., 1981, Avian Dis. 25:1027-1033.
Mannose and lactose were shown to significantly reduce Salmonella typhimurium adherence to the ceca of chicks (Oyofo et al., 1989, Avian Dis. 33:531-534). The inhibitory effect of these sugars was believed to take place by blocking the receptor sites on the gut epithelium and on the microorganism pili. It has been shown that providing dietary lactose together with cecal flora contents to broiler chickens reduced the occurrence of Salmonella (Corrier et al., 1990, Avian Dis. (in press); Hinton et al., 1990, Avian Dis. (in press); Oyofo et al., 1989) . Historically, Lactobacillus administration (i.e., inclusion of viable cells in the feed) to animals has not yielded consistent benefits. There are many reasons for this including, for example, using Lactobacillus species or strains unadapted to or unsuitable for the animal being treated, or using conditions which do not produce a colonization of the Lactobacillus within the GI tract.
The object of this invention is to provide a food or feed additive formulation and method comprising isolated and identified pure cultures of Lactobacillus reuteri and/or other Lactobacillus species together with a sugar source such as lactose, using whey as a source for this sugar.
Lactobacillus reuteri was previously found to be recoverable from the stools of piglets after the piglets had been fed large quantities of the cells (co-pending application) . It was hypothesized in the co-pending application that such cells could be used, possibly in conjunction with glycerol, as a growth and health aid for these animals. Evidence has been obtained (and presented below) that L.reuteri may be administered to poultry as a means of competitively excluding salmonellae.
It is an object of this invention to provide a formulation that may be used as a food or food additive ixture that utilizes pure cultures of one or more of certain Lactobacillus species in addition to a sugar source.
It is a further object of the invention to provide a formulation that results in rapid weight gain for growing animals.
It is a further object of the invention to provide a formulation that decreases the number of pathogenic microorganisms in the gastrointestinal tract, with the purpose of adding any sugar for at least the purpose of being a source of carbohydrate for the metabolism of the Lactobacillus but not utilized by the animal or the unwanted microorganism(s) .
Other objects and advantages will be more fully apparent from the following disclosure and appended claims.
SUMMARY OF THE INVENTION The invention is for a formulated product that may be used as an animal feed additive and that includes isolated and identified pure culture(s) of naturally occurring gastrointestinalmicroorganisms, for example, Lactobacillus reuteri, L. animalis, and/or L. salivarius. The formulated product also includes a sugar source. The invention also includes a method of feeding the formulation to animals. Preferably the sugar source is whey, when animals which do not metabolize lactose such as chickens are used, because whey contains the sugar lactose and is an easily obtainable and voluminous waste product. The formulation of the invention when fed to animals provides a means to decrease populations of undesirable gastrointestinal microbes and results in increased weight gain of the animals, especially under the less than optimum growth conditions normally present in commercial livestock environments.
Other aspects and features of the invention will be more fully apparent from the following disclosure and appended claims.
DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS THEREOF The present invention provides a formulation usable as a food or feed additive for animals. In the particular invention, such animals specifically include all poultry and mammals, including human beings. The formulation for a particular animal comprises one or more pure cultures of a Lactobacillus species naturally occurring in the gastrointestinal tract of that animal and a source of a sugar that is metabolizable by the Lactobacillus species but not to any great extent by the animal. Thus, the formulation of the invention comprises:
(a) a bacterial culture comprising at least one live pure culture of a Lactobacillus species which occurs naturally in a particular animal group; and
(b) a source of sugar metabolizable by the Lactobacillus species in the bacterial culture but not metabolizable by the animals in the grou . By the term "group" is meant animals of a particular species or group of species which share in common a tendency to have a similar gastrointestinal Lactobacillus flora and a similar inability to metabolize a sugar which is metabolizable by the Lactobacillus flora. As discussed below, the formulation discussed in detail herein has been devised for poultry but is adaptable to other animals, and includes a source of lactose which is not metabolizable by poultry.
In the preferred embodiment, the formulation comprises live, pure cultures of at least one of Lactobacillus reuteri, L. animalis and L. salivarius, and a sugar source. The preferred sugar source is whey, because it is inexpensive and easily available, and because it contains lactose, a good source of carbon and energy for growth of the added microorganisms. An additional advantage of using a lactose source for feeding poultry or other birds is that birds do not utilize this sugar, and it is therefore readily available for the added microorganisms. Preferably, powdered whey is utilized as the lactose source to minimize shipping costs and spoilage prior to formulation of the additive. The preferred method of formulating the additive is as follows. L.reuteri. L.animalis and L.salivarius are grown individually in a variety of appropriate media used for lactobacilli. Lactose or maltose are the preferred sources of energy so that the cells are capable of rapid metabolism of the carbohydrates which may be present in the formulation or in the animals' food. The cells used for the preparation of the additive may be freshly harvested, frozen, lyophilized or suspended in oil or a specifically formulated diluent such as an aqueous solution. Commercially available whey powder or whey concentrate is used to formulate the additive. Although the cells and whey may be fed separately, the are preferably mixed together with or without other ingredients (e.g. corn, soybean meal, wheat, etc.). The mixture may be of a variety of microbe and whey mixtures, for example a solid and a solid (e.g. fine powder with granulated whey, etc.), a liquid and a solid (cell suspension and whey), a solid and a liquid (lyophilized cells and. a liquid whey concentrate) or a liquid and a liquid (liquid cell suspension and a liquid whey concentrate) . The additive final presentation of the mixture could be as a powder, granules, or pellets or liquid. Animals may be fed the additive in a variety of ways: for example, (1) the additive may be combined with dry feed during feed milling or when the feed is delivered to the animals; (2) the additive may be sprinkled on the food as a powder; or (3) the additive may be mixed in the drinking water. Preferably, to minimize labor, the additive is mixed with dry feed.
The features and advantages of the present invention will be more clearly understood by reference to the following examples, which are not to be considered as limiting the invention.
EXAMPLES Example l. Growth of Turkey Poults to be Fed Additive Experimentally
One day old Nicholas turkey torn poults are used in this study. The poults are not toe clipped, desnooded or wing clipped, nor are they given any vaccinations.
The turkeys are placed in animal rooms at the Dearstyne Poultry Research Center, Department of Poultry Science at NCSU's Agricultural Research Service (NCARS). The animal rooms have controlled ambient temperature, day length and thermostatically controlled Petersime brooding batteries (Petersime Incubator Co., Petersime, OH). A normal turkey starter diet, for example as shown in Table 1 with and without whey powder, is used throughout the trial. The amount of whey in the diet allows for a final 2.2% lactose. The trial is twenty days in duration, covering the period from day of hatch to day 12. The turkeys are weighed on Day 0 (at hatch), Day 5, Day 12, Day 15 and Day 20.
Figure imgf000015_0001
turkeys, are the strains which are used. The Lactobacillus strains are grown in LCM medium utilizing lactose or maltose for 24 h at 37°C, harvested by centrifugation, and washed twice with fresh basal medium as previously described (Axelsson et al., 1989, Microbial Ecol. Health Dis. 2:131-136; Chung et al., 1989, Microbial Ecol. Health Dis. 2:137-144). These cells are mixed into the animal feed at a level of approximately 105 CFU g'1 of feed. This inoculum level has been shown to effectively enhance the population level of this microorganism in the chicken ceca (Casas et al., 1990, in preparation). The number of L♦ reuteri in the feed and in the ceca are monitored as previously described (Chung et al., 1989, Microbiol. 56: 943-948). Appropriate dilutions are plated onto LBS agar and incubated anaerobically (Gas-Pak jars) at 37°C for 48 h. Plates containing about 50 to 200 CFU are overlaid with glycerol agar seeded with L. plantarum indicator cells, reincubated anaerobically for 24 h, and colonies showing growth inhibition zones counted as reute in-producing L.reuteri cells.
S. senf enberσ, isolated from turkeys, resistant to novobiocin and nalidixic acid, was obtained from Evillmar
Poultry Co. (Evillmar, MN) . Inocula for infectious challenge are prepared from cultures grown in BHI Broth (Difco Laboratories, Inc., Detroit, MI) and incubated at
37°C for 24 hours. The cultures are diluted appropriately in sterile 50 mM phosphate buffer, pH 7.0, to obtain challenge inocula containing 106 CFU per ml. Enumeration of these Salmonella is carried out by plating appropriate dilutions on Rembach Salmonella medium (Rembach, 1990,
Appl. Environ. Microbiol. 56:301-303).
Caecal content samples formicrobiological enumeration are prepared from sacrificed birds. Caeca are carefully removed from the birds and the open end of each is clipped. The exterior of the caecum is alcohol sterilized before transferring its contents to a stomacher bag for mixing and further dilution.
Example 3. Treatment of Poults
Turkey poults of Example 1 are subjected to the following eight treatments with two pens of 15 birds per pen being in each group:
Salmonella senftenberg infected group 1. Control, no whey, no L.reuteri
2. No whey, L.reuteri
3. Whey, no L.reuteri
4. Whey, L.reuteri
L.reuteri, when administered is mixed into the feed. The inoculated feed is changed every two days to guarantee the presence of viable L. reuteri in the feed. Whey is added to the feed, before milling, for a final 5% lactose concentration. Alternatively, L. reuteri and concentrated or dehydrated whey are formed into tablets , or added together in any product in which both components in a liquid or solid form have been previously combined, and the combination added to the feed of the animals.
5. senftenberg (106 CFU per ml) is crop fed by the means of an animal feeding stainless steel needle attached to a hypodermic syringe on day 5 after hatch. Example 4. Results of Addition of Lactobacillus, Whey and Salmonella
Salmonella senftenberg in feces and caecal contents of poults treated as in Example 3 is shown in Tables 2 and 3, respectively. The effect of L. reuteri and whey on the number of S. senftenberg in feces (droppings) becomes obvious at 72 h after Salmonella challenge. The data indicate a synergistic effect when whey and L. reuteri are added together.
The presence of S. senftenberg in caecal contents is presented in Table 3. The results show that addition of L. reuteri and/or whey, but in particular, the combination of . reuteri and whey, is effective in reducing the presence of S. senf enberg in the ceca of these animals. Thus, whereas 47% of the control ceca tested positive for S. senftenberg, none (0%) of the samples tested positive when fed L. reuteri and whey.
TABLE 2. Log10 CFU of S. senftenberg per g feces 72 h post challenge.
Figure imgf000018_0001
TABLE 3. Percent of cecal samples testing positive for S. senftenberg and L. reuteri 7 days post challenge
Figure imgf000019_0001
1 Positive samples had > 107 CFU/g
2 Positive samples had < 103 CFU/g
Example 5. Growth of Cold Stressed Poults Fed with L. reuteri and Whey
Instead of exposing turkey poults to constant temperature rooms as in Example 1, the temperature in the pens of cold stressed birds is 90 degrees F for 1 hour, then 85 degrees G for 2 hours in an on-off cycling for 48 hours after hatch. The temperature is then set back to normal brooding temperature for the remainder of the experiment, normal brooding temperature being 90 degrees F for the first seven days after hatch, 85 degrees F from day 7 to day 10, and 75 to 80 degrees after day 10.
Turkey poults are subjected to the following four treatments, with eight pens of eight birds per pen being in each treatment group:
1. Control, no whey, no L. reuteri 2. No whey, L. reuteri 3. Whey, no L. reuteri
4. Whey, L. reuteri
Example 6. Results of Growth of Cold Stressed Poults
Relative wights of poults treated as in Example 5 , at 0, 5, 10, 15, and 20 days of age are shown in Table 4. The beneficial effect of whey becomes evident at day 5, while the effect of L. reuteri becomes obvious at days 15 and 20.
TABLE 4. Effect of L. reuteri and whey on body weight of turkey poults.
TREATMENTS RELATIVE WEIGHT (PERCENT) AT
Day 0 Day 5 Day 10 Day 15 Day 20
Figure imgf000020_0001
For percentage conversion, control weights (no whey, no L. reuteri) at each weight day were made equal to 100%.
Example 1. Use of Lactobacillus salivarius and
Lactobacillus animalis L. salivarius subsp. salivarius ATCC type strain No. 11741 and L. animalis ATCC type strain No. 35046 are grown as in Example 2. Each strain is added individually to feed as in Example 3. The feed is augmented with whey according to Example 3. The feed is used to feed chickens and turkeys to decrease undesirable microbial organisms and improve poultry weight gain.
Example 8. Use of Multiple Lactobacillus Strains
Strains of the three Lactobacillus species discussed in Examples 3 and 8 are each added individually, or as a mixed inoculum to the whey-augmented feed according to Example 3. The feed containing the three strains is used to feed turkeys and chickens.
BEST MODE FOR CARRRYING OUT THE INVENTION
The food or feed additive for animals, such as poultry and mammals, including human beings, comprises one or more pure cultures of a Lactobacillus species naturally occurring in the gastrointestinal tract of that animal and a source of a sugar that is metabolizable by the Lactobacillus species but not to any great extent by the animal. Preferably, the formulation comprises live, pure cultures of at least one of Lactobacillus reuteri. L. animalis and L. salivarius, and a sugar source. The preferred sugar source is whey, particularly for poultry. Whey is inexpensive and easily available, contains lactose, a good source of carbon and energy for growth of the added microorganisms, and is not utilized poultry or other birds and therefore readily available for the added microorganisms. Preferably, powdered whey is utilized as the lactose source to minimize shipping costs and spoilage prior to formulation of the additive.
The preferred method of formulating the additive is as follows. L.reuteri, L.animalis and L.salivarius are grown individually in a variety of appropriate media used for lactobacill. The cells used for the preparation of the additive may be freshly harvested, frozen, lyophilized or suspended in oil or a specifically formulated diluent such as an aqueous solution. Commercially available whey powder or whey concentrate is used to formulate the additive. The cells and whey are preferably mixed together with or without other ingredients (e.g. corn, soybean meal, wheat, etc.). Animals are preferably fed the additive as a mixture with dry feed.
INDUSTRIAL APPLICABILITY The invented formulation may be used as a food or food additive mixture for animals grown commericially, such as poultry. It provides a product that results in rapid weight gain for growing animals, and decreases the number of pathogenic microorganisms in the gastrointestinal tract, thereby resulting in increased productivity and decreased animal mortality.
While the invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments are possible, and accordingly, all such variations, modifications and embodiments are to be regarded as being within the spirit and scope of the invention.

Claims

THE CLAIMSWhat Is Claimed Is:
1. A formulation for oral administration to an animal of a particular group, comprising: (a) a bacterial culture comprising at least one live pure culture of at least one Lactobacillus species which occurs naturally in a particular animal group; and (b) a source of sugar metabolizable by the Lactobacillus species in the bacterial culture but not metabolizable by the animals in the group.
2. A formulation for oral administration according to Claim 1, comprising a Lactobacillus culture selected from the group consisting of L.reuteri, L.salivarius and L.animalis, and the animals are poultry.
3. A formulation for oral administration according to Claim 1, wherein the source of sugar comprises whey.
4. A formulation for oral administration according to Claim 1, wherein the Lactobacillus culture is selected from the group consisting of L.reuteri, L.salivarius and L.animalis, and the source of sugar is whey.
5. A formulation for oral administration according to Claim 4, further comprising glycerol.
6. A formulation for oral administration according to Claim 1, wherein pure cultures of L.reuteri. L.salivarius and L.animalis are used, and the sugar is lactose.
7. A formulation for oral administration according to Claim 6, wherein the source of lactose is whey.
8. A formulation for oral administration to animals, comprising: (a) a bacterial culture consisting of at least one live, pure culture of Lactobacillus: and (b) a source of sugar.
9. A formulation for oral administration according to Claim 8, comprising a Lactobacillus culture selected from the group consisting of L.reuteri. L.salivarius and L.animalis. and the animals are poultry.
10. A formulation for oral administration according to Claim 8, wherein the source of sugar comprises whey.
11. A formulation for oral administration according to Claim 8, wherein the Lactobacillus culture is selected from the group consisting of L.reuteri, L.salivarius and L.animalis. and the source of sugar is whey.
12. A formulation for oral administration according to Claim 11, further comprising glycerol.
13. A formulation for oral administration according to Claim 8, wherein pure cultures of L.reuteri. L.salivarius and L.animalis are used, and the sugar is lactose.
14. A formulation for oral administration according to Claim 13, wherein the source of lactose is whey.
15. A method of decreasing numbers of undesirable microbes in an animal's gastrointestinal tract, comprising: (a) obtaining at least one pure culture of Lactobacillus cells;
(b) obtaining a source of sugar; and
(c) administering the Lactobacillus cells and the sugar orally to the animal.
16. A method of decreasing numbers of undesirable microbes in gastrointestinal tracts of animals, comprising:
(a) obtaining at least one pure culture of Lactobacillus cells;
(b) obtaining a source of sugar metabolizable by the Lactobacillus cells and not to a significant extent by the animals or the undesirable microbes; and
(c) administering the Lactobacillus cells and the sugar orally to the animal.
PCT/US1991/003796 1991-08-01 1991-08-01 Method and formulation for reducing microbial populations WO1993002558A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1991/003796 WO1993002558A1 (en) 1991-08-01 1991-08-01 Method and formulation for reducing microbial populations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/003796 WO1993002558A1 (en) 1991-08-01 1991-08-01 Method and formulation for reducing microbial populations

Publications (1)

Publication Number Publication Date
WO1993002558A1 true WO1993002558A1 (en) 1993-02-18

Family

ID=22225569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/003796 WO1993002558A1 (en) 1991-08-01 1991-08-01 Method and formulation for reducing microbial populations

Country Status (1)

Country Link
WO (1) WO1993002558A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US5533973A (en) * 1995-01-13 1996-07-09 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
WO1999043370A1 (en) 1998-02-27 1999-09-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US6080132A (en) * 1998-02-27 2000-06-27 Abbott Laboratories Apparatus for altering characteristics of a fluid
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
US6309373B1 (en) 1998-08-12 2001-10-30 Abbott Laboratories Apparatus for altering the characteristics of a fluid
ES2292322A1 (en) * 2005-10-20 2008-03-01 Institut De Recerca I Tecnologia Agroalimentaries New bacterial strains pure biological cultures for preparing compositions that eliminate colonization by pathogenic strain of species of Salmonella of gastrointestinal tract in domestic birds, are formed of two bacterial strains
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US7906112B2 (en) 2003-12-19 2011-03-15 The Procter & Gamble Company Canine probiotic Lactobacilli
US7998473B2 (en) 2003-12-19 2011-08-16 The Procter & Gamble Company Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium
US8034601B2 (en) 2005-05-31 2011-10-11 The Procter & Gamble Company Feline probiotic bifidobacteria
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US8809035B2 (en) 2003-12-19 2014-08-19 The Iams Company Canine probiotic Bifidobacterium
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US9192177B2 (en) 2005-05-31 2015-11-24 The Iams Company Feline probiotic Lactobacilli
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984575A (en) * 1974-02-06 1976-10-05 Microlife Technics, Inc. Bacterial compositions for changing the digestive system bacteria in animals
US3988440A (en) * 1973-10-11 1976-10-26 Dso "Pharmachim" Remedy for treating gastritis, gastric and duodenal ulcers
US4314995A (en) * 1976-02-23 1982-02-09 Seikenkai Pharmaceutical lactobacillus preparations
US4518696A (en) * 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US4591499A (en) * 1984-01-20 1986-05-27 J. B. Lima, Inc. Method for treatment and prevention of mastitis
JPS62130680A (en) * 1985-12-03 1987-06-12 Karupisu Shokuhin Kogyo Kk Novel lactic acid bacteria
US4689226A (en) * 1980-01-11 1987-08-25 Farmos-Yhtyma Oy Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry
US4946791A (en) * 1986-10-02 1990-08-07 Bio Techniques Laboratories, Inc. Novel strain of Lactobacillus acidophilus
US4980164A (en) * 1986-10-02 1990-12-25 Bio Techniques Laboratories, Inc. Strains of lactobacillus for enhancing feed conversion efficiency

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988440A (en) * 1973-10-11 1976-10-26 Dso "Pharmachim" Remedy for treating gastritis, gastric and duodenal ulcers
US3984575A (en) * 1974-02-06 1976-10-05 Microlife Technics, Inc. Bacterial compositions for changing the digestive system bacteria in animals
US4314995A (en) * 1976-02-23 1982-02-09 Seikenkai Pharmaceutical lactobacillus preparations
US4689226A (en) * 1980-01-11 1987-08-25 Farmos-Yhtyma Oy Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry
US4518696A (en) * 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US4591499A (en) * 1984-01-20 1986-05-27 J. B. Lima, Inc. Method for treatment and prevention of mastitis
JPS62130680A (en) * 1985-12-03 1987-06-12 Karupisu Shokuhin Kogyo Kk Novel lactic acid bacteria
US4946791A (en) * 1986-10-02 1990-08-07 Bio Techniques Laboratories, Inc. Novel strain of Lactobacillus acidophilus
US4980164A (en) * 1986-10-02 1990-12-25 Bio Techniques Laboratories, Inc. Strains of lactobacillus for enhancing feed conversion efficiency

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOBROGOSZ et al., "Regulatory and Protective Role of the Normal Microflora", published 1989, see pages 283-292. *
MICROBIAL ECOLOGY IN HEALTH AND SCIENCE, Volume 2, issued 1989, CHUNG et al., "In Vitro Studies on Reuterin Synthesis by Lactobacillus Reuteri", pages 137-144. *
POULTRY SCIENCE, Volume 70, Supplement 1, PARKHORST et al., issued 1991, "Lactobacillus Reuteri and Dietary Whey Effect on Twenty Day Body Weights of Turkey Poults Subjected to Either Cold or Low Protein Stress", p. 1-7. *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US5533973A (en) * 1995-01-13 1996-07-09 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
WO1996021480A1 (en) * 1995-01-13 1996-07-18 Abbott Laboratories Apparatus for altering composition of nutritional product
US5738651A (en) * 1995-01-13 1998-04-14 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US5755688A (en) * 1995-01-13 1998-05-26 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
WO1999043370A1 (en) 1998-02-27 1999-09-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US6080132A (en) * 1998-02-27 2000-06-27 Abbott Laboratories Apparatus for altering characteristics of a fluid
US6309373B1 (en) 1998-08-12 2001-10-30 Abbott Laboratories Apparatus for altering the characteristics of a fluid
US6620434B2 (en) 1999-07-01 2003-09-16 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
US11452303B2 (en) 2003-01-22 2022-09-27 Purina Animal Nutrition Llc Methods for feeding sows and for improving the health of young piglets
US10980250B2 (en) 2003-01-22 2021-04-20 Purina Animal Nutrition Llc Methods for feeding sows and for improving the health of young piglets
US10172376B2 (en) 2003-01-22 2019-01-08 Purina Animal Nutrition Llc Methods for feeding sows and for improving the health of young piglets
US9433232B2 (en) 2003-01-22 2016-09-06 Purina Animal Nutrition Llc Methods for feeding sows and for improving the health of young piglets
US9078457B2 (en) 2003-01-22 2015-07-14 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
US8809035B2 (en) 2003-12-19 2014-08-19 The Iams Company Canine probiotic Bifidobacterium
US9580680B2 (en) 2003-12-19 2017-02-28 Mars, Incorporated Canine probiotic bifidobacterium pseudolongum
US8840880B2 (en) 2003-12-19 2014-09-23 The Iams Company Canine probiotic bifidobacteria globosum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8900569B2 (en) 2003-12-19 2014-12-02 The Iams Company Method of treating diarrhea in a canine
US8900568B2 (en) 2003-12-19 2014-12-02 The Iams Company Method of treating diarrhea in a canine
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US7906112B2 (en) 2003-12-19 2011-03-15 The Procter & Gamble Company Canine probiotic Lactobacilli
US9821015B2 (en) 2003-12-19 2017-11-21 Mars, Incorporated Methods of use of probiotic bifidobacteria for companion animals
US8802158B2 (en) 2003-12-19 2014-08-12 The Iams Company Methods of use of probiotic Lactobacilli for companion animals
US7998473B2 (en) 2003-12-19 2011-08-16 The Procter & Gamble Company Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal
US9427000B2 (en) 2005-05-31 2016-08-30 Mars, Incorporated Feline probiotic lactobacilli composition and methods
US9404162B2 (en) 2005-05-31 2016-08-02 Mars, Incorporated Feline probiotic bifidobacteria and methods
US9192177B2 (en) 2005-05-31 2015-11-24 The Iams Company Feline probiotic Lactobacilli
US8034601B2 (en) 2005-05-31 2011-10-11 The Procter & Gamble Company Feline probiotic bifidobacteria
ES2292322A1 (en) * 2005-10-20 2008-03-01 Institut De Recerca I Tecnologia Agroalimentaries New bacterial strains pure biological cultures for preparing compositions that eliminate colonization by pathogenic strain of species of Salmonella of gastrointestinal tract in domestic birds, are formed of two bacterial strains
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10709156B2 (en) 2008-07-07 2020-07-14 Mars, Incorporated Pet supplement and methods of making
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Similar Documents

Publication Publication Date Title
Jadhav et al. Probiotics in broiler poultry feeds: A review
JP4623896B2 (en) Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals
US5951977A (en) Competitive exclusion culture for swine
CN101262779B (en) Probiotic health or fitness promoting foodstuff, feed, and/or drinking water additive and use thereof
WO1993002558A1 (en) Method and formulation for reducing microbial populations
EP0987957A1 (en) Method for administering viable microorganism composition for poultry
WO2007058027A1 (en) Harmful bacterium control agent containing bacillus thuringiensis
Deniz et al. Effects of probiotic (Bacillus subtilis DSM 17299) supplementation on the caecal microflora and performance in broiler chickens
Wang et al. Assessment of probiotic properties of Lactobacillus plantarum ZLP001 isolated from gastrointestinal tract of weaning pigs
KR20190051771A (en) Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same
CA2100774C (en) Feed additive and method
Husmaini et al. Growth and survival of lactic acid bacteria isolated from by-product of virgin coconut oil as probiotic candidate for poultry
US20140037605A1 (en) Anticoccidial composition
KR20090078065A (en) The composition of improved lactic acid bacteria feed additive and method for manufacturing thereof
JP2006169197A (en) Antimicrobial agent for livestock and composition for feed
Hidayat et al. Total of Escherichia coli excreta broiler given Enterococcus sp. as probiotics candidate of poultry
US8673290B2 (en) Sporulation-deficient B. texasporus cells and methods for efficient and cost-effective inactivation and use thereof
FI112374B (en) Method for the administration of direct-fed microorganisms to poultry in ovo
WO1995004539A1 (en) Immunopotentiator and method of immunopotentiating animal with the same
RU2779603C1 (en) Feed additive with phytoprobiotic activity for the prevention and treatment of poultry diseases
Oliveira et al. In Vitro Selection and In Vivo Trial of Lactobacillus strains for use a potential probiotics for laying hens
Guo et al. Comparative evaluation of three Lactobacilli with strain-specific activities for rats when supplied in drinking water
Oliveira et al. In vitroSelection and In vivoTrial of Lactobacillus Strains for Use a Potential Probiotics for Laying
Ivanov Laboratory study to determine the effect of a probiotic mixture on chicken-broiler
WO2012063345A1 (en) Immunopotentiating agent, immunopotentiating composition containing same, and immunopotentiating method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA FI JP KP KR NO SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA